Core Viewpoint - Yida Co., Ltd. plans to acquire 85% equity of Wanquan Biotechnology (Taizhou) Co., Ltd. from Wanquan Co., Ltd. for 24.565 million yuan, aiming to enhance its production capacity and product line in the fine chemical sector [1] Group 1 - The acquisition will make Wanquan Biotechnology a subsidiary of Yida Co., Ltd. [1] - The purpose of the acquisition is to leverage Wanquan's production experience and sales channel advantages [1] - The collaboration aims to promote the construction and investment of epoxy propylene (ethylene) derivatives in the fine chemical field [1] Group 2 - The transaction is expected to optimize Yida's capacity layout and enrich its product offerings [1] - The acquisition is intended to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan [1] Group 1: Acquisition Details - The acquisition involves the purchase of 85% equity in Wanqi Biotechnology (Taizhou) Co., Ltd. by the company's subsidiary, Taixing Yida Chemical Co., Ltd. [1] - The total investment for this acquisition is 24.565 million yuan [1] Group 2: Strategic Objectives - The acquisition is part of the company's strategy to promote high-end and refined product development [1] - The company intends to leverage Wanqi's years of production experience and sales channel advantages to advance the construction of epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - This move is expected to optimize the company's capacity layout, enrich its product line, and enhance production capabilities to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan, leveraging Wanqi's production experience and sales channels to optimize its capacity and product line [1] Group 1 - The acquisition amount is 24.565 million yuan [1] - The acquired company holds an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. [1] - The strategic goal is to promote high-end and refined product development [1] Group 2 - The collaboration will focus on the construction and investment in epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - The acquisition is expected to enhance the company's production capacity to effectively meet downstream customer demands [1] - The move is part of the company's strategy to optimize its capacity layout and enrich its product line [1]